Novartis COVID-19 Therapy Could Overcome Escape Variant Problem

Protein Therapeutic Enters Pivotal Trial

 
• By Andrew McConaghie
Novartis
Novartis is using a novel Phase II/III trial design to produce fast results in patients with early stage COVID-19 infections.

More from Business

More from Scrip